• Group revenue of $6.5m in Q1 FY26, up 30% pcp
• Oli6® Nutritional sales up 56% pcp to $4.0m
• Practitioner business sales up 46% QoQ to $2.6m

Nuchev Limited (ASX: NUC) has reported its Quarterly Activities Report and Appendix 4C for the first quarter of FY26. The company delivered strong results, with group revenue of $6.5m, up 30% compared to the previous corresponding period (pcp). This was driven by a 56% increase in Oli6® Nutritional sales to $4.0m, and a 46% quarter-on-quarter (QoQ) increase in Practitioner business sales to $2.6m. The company's entry into the Vietnam market in March 2025 contributed $0.6m in sales for the quarter. Oli6® Nutritional sales in the ANZ Grocery and Pharmacy channels were up 35% pcp to $1.8m, while Oli6® scan sales in ANZ were up 36% on a moving annual total (MAT) basis, significantly outpacing the total infant formula category growth of 2% MAT. China CBEC sales of Oli6® Nutritionals were $1.6m, up 31% pcp. The company's new product development (NPD) pipeline continues to deliver incremental sales, with the launch of Oli6® Grow in October 2025 contributing $0.1m in the quarter. The company's exclusive Sales Agency Agreement with Brauer and H&S Brands also generated an additional $0.2m in the quarter. Net cash outflows used in operating activities were $3.1m, impacted by the timing of production costs and delayed cash receipts, which have since been received. Adjusting for this, the company's net cash outflows would have been $1.9m, with cash at the end of the quarter of $3.6m. The company remains focused on driving the business to profitability through continued growth in Vietnam, its NPD pipeline, and the Practitioner business.

The company expects to deliver continued growth in the Vietnam market, with sales of $2.2m in the last twelve months. The company is also focused on converting its NPD pipeline into sales, which will allow the group to achieve positive operating cashflows and profit.